Streetbeat News

Regulatory

DWAC

SPY

Former President Donald Trump has claimed, without providing evidence, that he has been informed by the special counsel that he is a target in the January 6 grand jury probe. This news was shared on Trump's social media platform, Truth Social.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 1:33 pm

BPTS

Biophytis SA's shares are surging after the company concluded an agreement with SEQENS to produce the active compound in Sarconeos (BIO101), its main drug candidate. The drug is being developed for severe forms of Covid-19, sarcopenia, and Duchenne muscular dystrophy. Biophytis recently filed for FDA approval to launch its SARA-31 program in the U.S., the first-ever Phase 3 study in sarcopenia.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:19 pm

PIRS

Shares of Pieris Pharmaceuticals have been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 1:13 pm

KPTI

Karyopharm Therapeutics Inc's shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis. The company initiated a pivotal Phase 3 trial in June 2023 and plans to expand its clinical development program in myelofibrosis. Top-line data from the Phase 3 study is expected in 2025. KPTI shares are up 20.90% at $1.85 during the premarket session.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:12 pm

ARDS

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares are gaining after the company announced positive feedback from the European Medicines Agency on its proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301. The agreements by the EMA were similar to those agreed by the FDA. The company's shares are up 29.40% at $0.34 during the premarket session.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:09 pm

AZN

SNY

The FDA has approved AstraZeneca and Sanofi's Beyfortus for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The approval covers children up to 24 months of age. Beyfortus was approved in the EU in November 2022 and applications are under review in China, Japan, and other countries. The drug will be available in the US before the 2023-2024 RSV season.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 1:07 pm

FXI

China plans to deepen the role of state companies in the energy, resources, and grain sectors, according to Bloomberg. This move could potentially impact the iShares China Large-Cap ETF (FXI), which includes state-owned companies.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 1:01 pm

SCHW

Schwab has announced that it expects to face a one-time special assessment of $160M from the Federal Deposit Insurance Corporation (FDIC) later this year.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 12:59 pm

FXI

China's Vice Premier has urged for deepening state firm reforms, according to Xinhua. The potential impact on the iShares China Large-Cap ETF (FXI) is unclear.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 12:58 pm

T

VZ

Verizon Communications Inc (VZ) is investigating potential lead contamination linked to its aging phone cables. The company is testing sites where lead was reported to be leaching into the ground from old wiring. The issue could increase cleanup costs and lead to a difficult year for telecom operators. AT&T Inc (T) also owns some of these legacy networks.

Portfolio Pulse from Lekha Gupta

July 18, 2023 | 12:54 pm